Astria Therapeutics (ATXS) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025 summary

Strategic pipeline overview

• Focus on developing first-choice therapies for allergic and immunologic diseases, with navenibart and STAR-0310 as lead programs.

• Navenibart targets hereditary angioedema (HAE) with a monoclonal antibody inhibiting plasma kallikrein; Phase III ALPHA-ORBIT trial to start this quarter, top-line results expected early 2027.

• STAR-0310, an OX40 antagonist for atopic dermatitis, began Phase Ia in healthy subjects after IND clearance in December; results expected Q3 2025.

• Both programs emphasize patient-friendly dosing and administration, aiming for infrequent dosing and reduced treatment burden.

Navenibart clinical development and differentiation

• Phase I and II data show over 91% reduction in HAE attacks, with up to two-thirds of patients attack-free for six months.

• No injection site pain or tolerability concerns observed; formulation supports both prefilled syringe and auto-injector options.

• ALPHA-SOLAR open-label extension collects long-term safety and efficacy data for 300 mg Q3 months and 600 mg Q6 months; initial data expected mid-2025.

• ALPHA-ORBIT Phase III trial will test flexible dosing regimens, allowing patient and clinician choice between Q3 and Q6 month intervals.

• Modeling suggests efficacy comparable or superior to TAKHZYRO, with reduced dosing frequency and improved patient experience.

Market landscape and patient needs

• HAE market shows willingness to switch for convenience, as seen with ORLADEYO's uptake despite lower efficacy.

• Injection site pain and frequent dosing are significant burdens; navenibart aims to address both with its formulation and dosing schedule.

• Launch strategy includes both prefilled syringe and auto-injector to ease transition for current patients.